About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Testing of Cancer Therapy in Humans Culminates Life Work

by Kathy Jones on March 27, 2011 at 8:13 PM
Font : A-A+

 Testing of Cancer Therapy in Humans Culminates Life Work

A cancer-fighting antibody, originally is being used to treat humans in a phase 1 clinical trial. It was identified by a researcher from the Queensland Institute of Medical Research.

The trial is the culmination of many years' work for Prof Andrew Boyd, head of QIMR's Leukaemia Foundation Laboratory.

Advertisement

Phase I clinical trials, commenced using KB004, are the first step in a systematic process to determine if a drug might be efficacious in humans.

The monoclonal antibody has been shown to kill certain types of cancerous tumours in a laboratory using human samples.

It is targeted towards EphA3 expressing hematologic malignancies, which are believed to account for about 50 percent of acute leukaemias as well as a number of other human cancers, including a significant proportion of malignant melanomas, brain tumours and lung cancers.
Advertisement

Boyd said the journey from the initial identification of the antibody to the stage of clinical testing has been long but very rewarding.

"The KB004 project has a special place in my heart as it originated in my own lab many years ago. Although it now involves two other research groups in Australia and a U.S. company, there is a sense of nearing the goal I set out to achieve when I first started my research career," he said.

KaloBios Pharmaceuticals, a South San Francisco biotech company took the original mouse antibody and through a process known as Humaneering (tm) technology, developed an antibody that could be used in humans, as it would be more likely to be tolerated by the human immune system.

"The initiation of a Phase I clinical trial in patients with acute leukaemia by KaloBios is an important landmark and will hopefully lead to further testing and the ultimate use of this antibody as a treatment. It is highly significant to me that the phase I trial is in leukaemia, the disease that drove me to the initial discovery," said Boyd.

The antibody works by targeting a receptor protein found thus far in cancer cells and not on normal white blood cells or normal stem cells. It is hoped it will be well tolerated in patients with little or no side effects.

The development of this antibody as anti-cancer therapeutic was a collaboration between Boyd, Prof Andrew Scott from the Ludwig Institute and Associate Prof Martin Lackmann from Monash University, who initiated and lead the translational aspects of this venture.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Reiki and Pranic Healing Cancer Facts Cancer Tattoos A Body Art Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Most Popular on Medindia

Blood Donation - Recipients Accident and Trauma Care Calculate Ideal Weight for Infants Find a Hospital Drug Interaction Checker Iron Intake Calculator Blood Pressure Calculator Post-Nasal Drip Blood - Sugar Chart Diaphragmatic Hernia
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Testing of Cancer Therapy in Humans Culminates Life Work Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests